NCT01813799View on ClinicalTrials.gov

Study of DA-9801 to Treat Diabetic Neuropathic Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Diabetic Neuropathies
Interventions
DRUG

DA-9801 300mg

300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.

DRUG

DA-9801 600mg

600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.

DRUG

DA-9801 900mg

900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.

DRUG

Placebo

Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.

Trial Locations (1)

561-712

Chonbuk National University Hospital, Jeonju

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT01813799 - Study of DA-9801 to Treat Diabetic Neuropathic Pain | Biotech Hunter | Biotech Hunter